Text saying Media Center, our online resource featuring the latest news about our company over a pixelated background graphic

Media Center

Our online resource featuring the latest news about our company.

Recent News, Blogs and Articles

July 30, 2025

icon

Press Release

Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

July 30, 2025

icon

Press Release

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

July 30, 2025

icon

Press Release

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease

July 21, 2025

icon

Press Release

Eisai to Present Four-Year Efficacy and Safety Data on Continuous Treatment With Lecanemab at the Alzheimer's Association International Conference 2025

Explore All Articles

Explore All Blogs

Explore All Press Releases

Media Resources

Corporate Fact Sheet

Learn more about Eisai Inc.

Exton Fact Sheet

Learn more about our Exton, PA campus

Digital Asset Library

Find logos, images, videos

Contact Information

For media inquiries, please contact:

Corporate

Chris Vancheri
Associate Director, Corporate
Communications

551-305-0050

551-305-0050
Christopher_Vancheri@eisai.com

Neurology

Libby Holman
Senior Director, Product
Communications

201-753-1945

201-753-1945
Libby_Holman@eisai.com

Oncology

Michele Randazzo
Senior Director, Product
Communications

201-248-2228

201-248-2228
Michele_Randazzo@eisai.com

Investor

For current investors or those interested in becoming investors, please click below to be connected with the global Eisai Investor page.

Investor Info

Social Media

Stay up to date on everything Eisai.